Abstract:Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (Abeta) has become a major therapeutic target. Many efforts are underway to either reduce the production of Abeta or enhance its clearance. In 1999, Schenk and colleagues first showed that active immunization with full-length Abeta lowered cerebral Abeta levels in transgenic mice. These findings have been confirmed and extended in various transgenic mouse models of AD using both active and passive Abeta immunization. Cognitive improvement also has been reported in association with active and passive Abeta vaccination in AD-like mouse models, even in the absence of significant reductions in cerebral Abeta loads. In 2004, the authors reported that active immunization with full-length Abeta in aged nonhuman primates, Caribbean vervets, reduced cerebral Abeta levels and gliosis. Proposed mechanisms of Abeta clearance by immunotherapy include disruption of Abeta aggregates, Abeta phagocytosis by microglia, neutralization of Abeta oligomers at the synapse, and increased efflux of Abeta from brain to blood. A phase IIa clinical trial was halted in 2002 because of the appearance of meningoencephalitis in approximately 6% of the AD patients. Although the exact cause of these adverse events is unknown, the immunogen, full-length Abeta1-42, may have been recognized as a self-antigen leading to an autoimmune response in some patients. Limited cognitive stabilization and apparent plaque clearance have been reported in subsets of patients who generated antibody titers. Currently, a passive immunization trial with a recombinant humanized monoclonal Abeta antibody is underway in humans. In the meantime, the authors are developing novel Abeta peptide immunogens for active immunization to target Abeta B cell epitope(s) and avoid Abeta-specific T-cell reactions in order to generate a safe and effective AD vaccine. The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD.

Active Immunization with Norovirus P Particle-Based Amyloid-Β Chimeric Protein Vaccine Induces High Titers of Anti-Aβ Antibodies in Mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

New progress in active immunotherapy targeting to amyloid beta

Oral Administration of a Fusion Protein Between the Cholera Toxin B Subunit and the 42-Amino Acid Isoform of Amyloid-Β Peptide Produced in Silkworm Pupae Protects Against Alzheimer's Disease in Mice.

A Coimmunization Vaccine of Aβ42 Ameliorates Cognitive Deficits Without Brain Inflammation in an Alzheimer’s Disease Model

Recombinant Dna Vaccine Against Neurite Outgrowth Inhibitors Attenuates Behavioral Deficits and Decreases Abeta in an Alzheimer'S Disease Mouse Model

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Progress on Immunization with Amyloid-Beta in A Mouse Model of Alzheimer'S Disease

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

Short Amyloid-Beta Immunogens Show Strong Immunogenicity and Avoid Stimulating Pro-Inflammatory Pathways in Bone Marrow-Derived Dendritic Cells from C57BL/6J Mice in Vitro

Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice

A Biomimic Nanobullet with Ameliorative Inflammatory Microenvironment for Alzheimer's Disease Treatments

Effects of a 15-Amino-acid Isoform of Amyloid- Β Expressed by Silkworm Pupae on B6C3-Tg Alzheimer’s Disease Transgenic Mice

Active Beta-Amyloid Immunization Restores Spatial Learning in Pdapp Mice Displaying Very Low Levels of Beta-Amyloid

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

mRNA Vaccine for Alzheimer's Disease: Pilot Study

Human Anti-Beta-Amyloid Antibodies Block Beta-Amyloid Fibril Formation and Prevent Beta-Amyloid-Induced Neurotoxicity

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice